The Lumbagas Migraine Treatment is one of the most commonly prescribed medications for migraine headaches.
It’s also one of only a few medications to work with migraines, as well as other forms of chronic pain.
But a new study by researchers at Harvard Medical School suggests that it may be worth investigating if it works in people who don’t have other options.
“There are a number of studies showing that the Lumbaga treatment does work, but they’re all very small and observational studies,” says David Schreiber, the study’s senior author and a professor of medicine at Harvard.
“What we’ve done is look at the long-term follow-up of patients in the Lombagos clinic.”
To do this, Schreib and his colleagues randomly assigned patients to either a double-blind, placebo-controlled study with a group of people who had already received the Lambastrel, or a double blind, placebo controlled study with no treatment group.
They also asked them to complete a questionnaire about their health, including if they had migrainias and had any chronic pain, as part of a more thorough questionnaire.
Then they tracked how long it took for the patients to be able to manage their migrainas and other chronic pain using a modified version of a smartphone app called Chronic Pain Checkup.
After that, the researchers asked the patients about how well the Largas treatment was working for them.
Patients who took the Lomazem had a higher overall satisfaction rating than those who had not, even after adjusting for other factors.
They reported more time spent at work and less time sitting in front of a computer, which was a side effect that was less common in those who took Larga.
But even if Largaflage didn’t work, the new study did not prove that it would work better than other treatments.
And there’s no reason to think that the treatment will always work, Schrieb says.
The study also found that patients who had migranes had significantly lower rates of migrainic complications than those with no migraina.
“It does suggest that there are a lot of factors that can influence how well Largaga is working for migraine,” he says.
Schreib says he plans to study more of these outcomes to see whether they could translate into longer-term outcomes for people who have chronic pain like migrainis.
But the most interesting thing, he says, is that it could also be a great tool for people with other types of pain.
People who suffer from chronic pain have a lower level of the hormone oxytocin, which has been linked to more empathy, emotional responsiveness and trust.
So the Lothagaras Largash could have an effect on helping people with chronic pain by lowering the need for oxytocins.
“In some ways, it could be the first of its kind,” he said.
“It’s a pretty exciting treatment.”
Follow Mike Pearl on Twitter: @mikepearl and on Facebook.